167 related articles for article (PubMed ID: 19628152)
1. Novel therapies in Hepatitis C virus. Preface.
Pockros PJ
Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
[No Abstract] [Full Text] [Related]
2. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
Yu ML; Dai CY; Huang JF; Chuang WL
Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
[No Abstract] [Full Text] [Related]
3. Optimal dosage of ribavirin.
Mangia A; Andriulli A
Hepatology; 2010 Sep; 52(3):1174. PubMed ID: 20812365
[No Abstract] [Full Text] [Related]
4. [Genotype 1 superresponder treat for only 24 weeks].
MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
[No Abstract] [Full Text] [Related]
5. Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
Kalal C; Shukla A; Mohanka R; Vora M; Patel P; Shah S
Hepatology; 2018 May; 67(5):2049-2050. PubMed ID: 29152769
[No Abstract] [Full Text] [Related]
6. Treatment duration for genotypes 2 and 3: still confusing after all these years.
Jensen DM
J Clin Gastroenterol; 2010 Sep; 44(8):527-8. PubMed ID: 20628314
[No Abstract] [Full Text] [Related]
7. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
Szalay F
Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
[No Abstract] [Full Text] [Related]
8. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
[No Abstract] [Full Text] [Related]
9. Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
Smith JA; Kalimullah FA; Erickson CP; Peng LS
Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437283
[TBL] [Abstract][Full Text] [Related]
10. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
[No Abstract] [Full Text] [Related]
11. Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough.
Shiffman ML; Rustgi VK
Gastroenterology; 2006 Oct; 131(4):1339-41. PubMed ID: 17030201
[No Abstract] [Full Text] [Related]
12. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
Diago M; Hassanein T; Rodés J; Ackrill AM; Sedarati F
Ann Intern Med; 2004 Jan; 140(1):72-3. PubMed ID: 14706990
[No Abstract] [Full Text] [Related]
13. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
[No Abstract] [Full Text] [Related]
14. Interferon for hepatitis C patients with psychiatric disorders.
Rifai MA; Bozorg B; Rosenstein DL
Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
[No Abstract] [Full Text] [Related]
15. [Assessment and monitoring of patients with chronic hepatitis C on antiviral therapy--state of the art in 2003].
Simon K; Szymczak A
Pol Arch Med Wewn; 2004 Jul; 112(1):891-8. PubMed ID: 15526854
[No Abstract] [Full Text] [Related]
16. Consensus interferon: tailored therapy and the impact of adherence.
Gonzalez SA
Dig Dis Sci; 2011 Mar; 56(3):631-4. PubMed ID: 21259073
[No Abstract] [Full Text] [Related]
17. [Treatment with pegylated interferon and ribavirin in patients co-infected by human immunodeficiency virus and hepatitis C virus].
Marcos Sánchez F; Albo Castaño MI; Casallo Blanco S
Rev Clin Esp; 2007 Mar; 207(3):150-1; author reply 151-2. PubMed ID: 17397643
[No Abstract] [Full Text] [Related]
18. Decade in review-HCV: hepatitis C therapy-a fast and competitive race.
Zeuzem S
Nat Rev Gastroenterol Hepatol; 2014 Nov; 11(11):644-5. PubMed ID: 25223875
[No Abstract] [Full Text] [Related]
19. Delaying HCV treatment in HIV-positive patients.
Carter M
IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
[No Abstract] [Full Text] [Related]
20. Hepatitis C drug development at a crossroads.
Nelson DR
Hepatology; 2009 Oct; 50(4):997-9. PubMed ID: 19787813
[No Abstract] [Full Text] [Related]
[Next] [New Search]
